摘要
精神障碍被认为是严重影响患者个性,批判性思维和感知能力的严重精神障碍。传统药理学方法的高发病率,全球传播和局限性给患者,医疗专业人员和医疗保健系统带来了重大负担。迄今为止,许多口服给药疗法可用于抑郁症,精神分裂症,焦虑症,双相情感障碍和自闭症谱系问题的处理。然而,水溶性差,口服吸收不稳定,首过代谢广泛,口服生物利用度低和半衰期短是限制这些药物的药学意义和治疗可行性的主要因素。近几十年来,基于纳米技术的递送系统已经获得研究人员的显着关注,以缓解与抗精神病药物相关的药物问题并优化其口服药物递送,治疗结果和患者依从性。因此,本综述旨在总结可用的体外和体内证据,表明晚期递送系统在改善抗精神病药物的水溶性,跨膜渗透性,口服生物利用度和治疗结果方面的药物重要性。
关键词: 抗精神病药物,水溶性,功效升级,纳米技术,口服生物利用度,药代动力学特征,精神障碍。
图形摘要
Current Drug Targets
Title:New Insight in Improving Therapeutic Efficacy of Antipsychotic Agents: An Overview of Improved In Vitro and In Vivo Performance, Efficacy Upgradation and Future Prospects
Volume: 19 Issue: 8
关键词: 抗精神病药物,水溶性,功效升级,纳米技术,口服生物利用度,药代动力学特征,精神障碍。
摘要: Psychotic disorders are recognized as severe mental disorders that rigorously affect patient’s personality, critical thinking, and perceptional ability. High prevalence, global dissemination and limitations of conventional pharmacological approaches compel a significant burden to the patient, medical professionals and the healthcare system. To date, numerous orally administered therapies are available for the management of depressive disorders, schizophrenia, anxiety, bipolar disorders and autism spectrum problems. However, poor water solubility, erratic oral absorption, extensive first-pass metabolism, low oral bioavailability and short half-lives are the major factors which limit the pharmaceutical significance and therapeutic feasibility of these agents. In recent decades, nanotechnology-based delivery systems have gained remarkable attention of the researchers to mitigate the pharmaceutical issues related to the antipsychotic therapies and to optimize their oral drug delivery, therapeutic outcomes, and patient compliance. Therefore, the present review was aimed to summarize the available in vitro and in vivo evidences signifying the pharmaceutical importance of the advanced delivery systems in improving the aqueous solubility, transmembrane permeability, oral bioavailability and therapeutic outcome of the antipsychotic agents.
Export Options
About this article
Cite this article as:
New Insight in Improving Therapeutic Efficacy of Antipsychotic Agents: An Overview of Improved In Vitro and In Vivo Performance, Efficacy Upgradation and Future Prospects, Current Drug Targets 2018; 19 (8) . https://dx.doi.org/10.2174/1389450117666161125174625
DOI https://dx.doi.org/10.2174/1389450117666161125174625 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Identify Compounds' Target Against Alzheimer's Disease Based on In-Silico Approach
Current Alzheimer Research Transcriptional Regulation and Expression of CYP3A4 in Hepatocytes
Current Drug Metabolism Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Stimulated CB1 Cannabinoid Receptor Inducing Ischemic Tolerance and Protecting Neuron from Cerebral Ischemia
Central Nervous System Agents in Medicinal Chemistry Single-chain Antibody Against Reg4 Suppresses Gastric Cancer Cell Growth and Enhances 5-FU-induced Cell Death in vitro
Anti-Cancer Agents in Medicinal Chemistry Advances in Encoding of Colloids for Combinatorial Libraries: Applications in Genomics, Proteomics and Drug Discovery
Current Pharmaceutical Biotechnology Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Somatostatin, Somatostatin Analogs and Somatostatin Receptor Dynamics in the Biology of Cancer Progression
Current Molecular Medicine Nanoparticles Based Intranasal Delivery of Drug to Treat Alzheimer’s Disease: A Recent Update
CNS & Neurological Disorders - Drug Targets Characteristic of Cyclodextrins: Their Role and Use in the Pharmaceutical Technology
Current Drug Targets Novel 1,2,4-Triazolo[3,4-b]-1,3,4-thiadiazole Derivatives as Dual Analgesic/Anti-inflammatory and Antimicrobial Agents
Letters in Drug Design & Discovery Process Optimization for Biodiesel Production
Recent Patents on Biotechnology Synthesis and Biological Activities of Sulfinyl Acetamide Derivatives for Narcolepsy Treatment
Letters in Drug Design & Discovery Contemporary Anticholinesterase Pharmaceuticals of Natural Origin and Their Synthetic Analogues for the Treatment of Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued) Behavioral Tasks Evaluating Schizophrenia-like Symptoms in Animal Models: A Recent Update
Current Neuropharmacology Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Inflammatory Mediators in Smoke Inhalation Injury
Inflammation & Allergy - Drug Targets (Discontinued)